Avidity Partners Management
Latest statistics and disclosures from Avidity Partners Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Pfizer Inc option, ABBV, SGEN, AVTR, MRK, and represent 31.23% of Avidity Partners Management's stock portfolio.
- Added to shares of these 10 stocks: Pfizer Inc option (+$239M), MRK (+$95M), BIIB (+$89M), AVTR (+$66M), IMAB (+$63M), Biogen Idec Inc option (+$61M), SGEN (+$55M), TMO (+$52M), ANTM (+$47M), DGX (+$46M).
- Started 45 new stock positions in CHNG, EPIX, TMO, TRIL, APLS, Nurix Therapeutics, ARYBU, Pmv Pharmaceuticals, Outset Med, MRK.
- Reduced shares in these 10 stocks: , IMMU (-$68M), ALXN (-$57M), EXEL (-$47M), HOLX (-$47M), , , Principia Biopharma (-$33M), ESPR (-$29M), VIR (-$25M).
- Sold out of its positions in AKUS, ALEC, ALXN, RCUS, ASND, AZN, AVDL, RNA, CCXI, CHRS.
- Avidity Partners Management was a net buyer of stock by $662M.
- Avidity Partners Management has $2.2B in assets under management (AUM), dropping by 38.19%.
Tip: Access up to 7 years of quarterly data
Positions held by Avidity Partners Management LP consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Avidity Partners Management
Companies in the Avidity Partners Management portfolio as of the September 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Pfizer Inc option Call Option | 11.1 | $239M | NEW | 6.5M | 36.70 | |
| Abbvie (ABBV) | 6.2 | $133M | 1.5M | 87.59 | ||
| Seattle Genetics (SGEN) | 4.8 | $104M | +111% | 531k | 195.69 | |
| Avantor (AVTR) | 4.8 | $103M | +183% | 4.6M | 22.49 | |
| Merck & Co (MRK) | 4.4 | $95M | NEW | 1.1M | 82.95 | |
| Biogen Idec (BIIB) | 4.1 | $89M | NEW | 315k | 283.68 | |
| Biohaven Pharmaceutical Holding (BHVN) | 3.9 | $84M | +16% | 1.3M | 65.01 | |
| Horizon Therapeutics Pub L SHS (HZNP) | 3.4 | $72M | +73% | 930k | 77.68 | |
| I Mab Sponsored Ads (IMAB) | 2.9 | $63M | NEW | 1.3M | 47.03 | |
| Biogen Idec Inc option Call Option | 2.8 | $61M | NEW | 214k | 283.68 | |
| Aurinia Pharmaceuticals (AUPH) | 2.4 | $53M | +44% | 3.6M | 14.73 | |
| Thermo Fisher Scientific (TMO) | 2.4 | $52M | NEW | 118k | 441.52 | |
| Bristol-myers Squibb Right 99/99/9999 (BMY.R) | 2.4 | $51M | +292% | 23M | 2.25 | |
| Baxter International (BAX) | 2.3 | $50M | -22% | 620k | 80.42 | |
Setup an alertAvidity Partners Management will file the next quarterly 13-HR in about 3 months. Would you like to be notified? |
||||||
| Anthem (ANTM) | 2.2 | $47M | NEW | 176k | 268.59 | |
| Quest Diagnostics Incorporated (DGX) | 2.1 | $46M | NEW | 402k | 114.49 | |
| Mirati Therapeutics (MRTX) | 2.1 | $46M | NEW | 275k | 166.05 | |
| Quidel Corporation (QDEL) | 1.8 | $39M | NEW | 177k | 219.38 | |
| Boston Scientific Corporation (BSX) | 1.7 | $37M | NEW | 967k | 38.21 | |
| Change Healthcare (CHNG) | 1.7 | $37M | NEW | 2.5M | 14.51 | |
| Natera (NTRA) | 1.7 | $36M | NEW | 503k | 72.24 | |
| Kadmon Hldgs (KDMN) | 1.6 | $35M | +40% | 9.0M | 3.92 | |
| Arvinas Ord (ARVN) | 1.5 | $32M | +25% | 1.3M | 23.61 | |
| Zentalis Pharmaceuticals (ZNTL) | 1.4 | $30M | +34% | 904k | 32.69 | |
| Syndax Pharmaceuticals (SNDX) | 1.3 | $27M | +21% | 1.9M | 14.76 | |
| Catalent (CTLT) | 1.3 | $27M | NEW | 318k | 85.66 | |
| Iovance Biotherapeutics (IOVA) | 1.2 | $26M | +8% | 799k | 32.92 | |
| Trillium Therapeutics Com New (TRIL) | 1.2 | $25M | NEW | 1.7M | 14.21 | |
| Bioxcel Therapeutics (BTAI) | 1.1 | $23M | +38% | 538k | 43.36 | |
| Humana (HUM) | 1.0 | $21M | NEW | 52k | 413.88 | |
| Anika Therapeutics (ANIK) | 1.0 | $21M | +65% | 602k | 35.39 | |
| Collegium Pharmaceutical Inc Common Stock Usd (COLL) | 1.0 | $21M | NEW | 1.0M | 20.82 | |
| Harpoon Therapeutics (HARP) | 0.9 | $20M | -2% | 1.2M | 16.99 | |
| Amarin Corp Spons Adr New (AMRN) | 0.9 | $19M | NEW | 4.5M | 4.21 | |
| Athira Pharma | 0.9 | $19M | NEW | 1.0M | 18.46 | |
| Medtronic SHS (MDT) | 0.9 | $19M | +4% | 181k | 103.92 | |
| Exelixis (EXEL) | 0.9 | $19M | -71% | 769k | 24.45 | |
| Apellis Pharmaceuticals (APLS) | 0.9 | $19M | NEW | 623k | 30.17 | |
| Akebia Therapeutics (AKBA) | 0.9 | $18M | NEW | 7.3M | 2.51 | |
| Adaptimmune Therapeutics Pls Sponds Adr (ADAP) | 0.8 | $17M | +44% | 2.1M | 7.98 | |
| Essa Pharma Com New (EPIX) | 0.7 | $14M | NEW | 2.1M | 6.90 | |
| Biontech Se Sponsored Ads (BNTX) | 0.7 | $14M | NEW | 206k | 69.23 | |
| Mersana Therapeutics (MRSN) | 0.7 | $14M | -29% | 757k | 18.62 | |
| Ideaya Biosciences (IDYA) | 0.6 | $13M | -21% | 1.1M | 12.56 | |
| Zymeworks (ZYME) | 0.5 | $11M | NEW | 245k | 46.58 | |
| Aldeyra Therapeutics (ALDX) | 0.5 | $11M | NEW | 1.4M | 7.41 | |
| Taysha Gene Therapies Com Shs | 0.4 | $8.8M | NEW | 392k | 22.40 | |
| Dynavax Technologies Corp Com New (DVAX) | 0.4 | $8.7M | -24% | 2.0M | 4.32 | |
| Axsome Therapeutics (AXSM) | 0.4 | $8.4M | -70% | 118k | 71.25 | |
| Iteos Therapeutics | 0.4 | $8.1M | NEW | 330k | 24.67 | |
| Ac Immune Sa SHS (ACIU) | 0.4 | $7.6M | NEW | 1.6M | 4.88 | |
| Alpine Immune Sciences (ALPN) | 0.3 | $7.1M | NEW | 810k | 8.79 | |
| Vesper Healthcare Acqstn Cor Unit 99/99/9999 | 0.3 | $6.2M | NEW | 600k | 10.26 | |
| Clovis Oncology (CLVS) | 0.3 | $5.8M | NEW | 1.0M | 5.83 | |
| Arya Sciences Acquisition Com Cl A (ARYBU) | 0.3 | $5.4M | NEW | 500k | 10.82 | |
| Oak Street Health | 0.2 | $5.3M | NEW | 100k | 53.44 | |
| Pmv Pharmaceuticals | 0.2 | $5.3M | NEW | 150k | 35.50 | |
| Outset Med | 0.2 | $5.0M | NEW | 100k | 50.00 | |
| Health Sciences Acq Corp 2 Ord Shs | 0.2 | $4.4M | NEW | 400k | 11.00 | |
| Panacea Acquisition Corp Unit 99/99/9999 | 0.2 | $3.6M | NEW | 300k | 12.00 | |
| Bctg Acquisition Corp | 0.1 | $3.1M | NEW | 300k | 10.36 | |
| Berkeley Lts | 0.1 | $1.9M | NEW | 25k | 76.36 | |
| Nurix Therapeutics | 0.1 | $1.7M | NEW | 50k | 34.92 | |
| Inozyme Pharma | 0.1 | $1.6M | NEW | 62k | 26.29 | |
| Accolade | 0.1 | $1.6M | NEW | 40k | 38.88 | |
| American Well Corp Cl A | 0.1 | $1.5M | NEW | 50k | 29.64 | |
| Relay Therapeutics | 0.1 | $1.3M | NEW | 30k | 42.60 | |
| Annexon | 0.1 | $1.1M | NEW | 38k | 30.24 | |
Past Filings by Avidity Partners Management
SEC 13F filings are viewable for Avidity Partners Management going back to 2019
- Avidity Partners Management 2020 Q3 filed Nov. 16, 2020
- Avidity Partners Management 2020 Q2 filed Aug. 14, 2020
- Avidity Partners Management 2019 Q4 amended filed June 17, 2020
- Avidity Partners Management 2020 Q1 amended filed June 17, 2020
- Avidity Partners Management 2020 Q1 filed May 15, 2020
- Avidity Partners Management 2019 Q4 filed Feb. 14, 2020